Showing results (21-30 of 136) with videos related to
Sort By:
Pageof 14
Journal of Medicinal Chemistry|March 10, 2015
Design and synthesis of norendoxifen analogues with dual aromatase inhibitory and estrogen receptor modulatory activitiesWei Lv, Jinzhong Liu, Todd C Skaar, et al.Naunyn-Schmiedeberg'S Archives of Pharmacology|July 11, 2002
Teaching rational prescribing: a new clinical pharmacology curriculum for medical schoolsDavid A Flockhart, Sally Usdin Yasuda, John C Pezzullo, et al.Nature Reviews. Cancer|October 13, 2006
Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinantsVered Stearns, Bryan Schneider, N Lynn Henry, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 23, 2010
Methadone: a substrate and mechanism-based inhibitor of CYP19 (aromatase)Wenjie Jessie Lu, Robert Bies, Landry K Kamden, et al.Chirality|September 22, 2011
Stereoselective pharmacokinetics of stable isotope (+/-)-[13C]-pantoprazole: Implications for a rapid screening phenotype test of CYP2C19 activityDavid L Thacker, Anil Modak, Phuong D Nguyen, et al.Pharmacogenetics and Genomics|April 28, 2010
Differential quantification of CYP2D6 gene copy number by four different quantitative real-time PCR assaysAnuradha Ramamoorthy, David A Flockhart, Naoya Hosono, et al.Journal of the National Comprehensive Cancer Network : JNCCN|February 10, 2009
Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?Michaela J Higgins, James M Rae, David A Flockhart, et al.Statistics in Medicine|March 16, 2007
Drug-drug interaction prediction: a Bayesian meta-analysis approachLang Li, Menggang Yu, Raymond Chin, et al.Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|June 12, 2003
Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trialKyung-Hoon Lee, Bryan A Ward, Zeruesenay Desta, et al.Breast Cancer Research and Treatment|August 5, 2011
The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agentsWenjie Jessie Lu, Cong Xu, Zifan Pei, et al.Pageof 14